Major ADHD Study Backed Drugs Over Therapy at a Cost
(HealthDay News) – Many children with attention-deficit hyperactivity disorder (ADHD) may have missed out on valuable counseling because of a widely touted study that concluded stimulants such as Ritalin or Adderall were more effective for treating the disorder than medication plus behavioral therapies, experts say.
That 20-year-old study, funded with $11 million from the U.S. National Institute of Mental Health, concluded that the medications outperformed a combination of stimulants plus skills-training therapy or therapy alone as a long-term treatment. But now, experts, including some of the study's authors, think that relying on such a narrow avenue of treatment may deprive children, their families, and their teachers of effective strategies for coping with ADHD, The New York Times reported Monday.
Professionals worry that the findings have overshadowed the long-term benefits of school- and family-based skills programs. The original findings also gave pharmaceutical companies a significant marketing tool – now more than two-thirds of American children with ADHD take medication for the condition. And insurers have also used the study to deny coverage of psychosocial therapy, which costs more than daily medication but may deliver longer-lasting benefits, according to the Times. According to the news report, an insured family might pay $200 a year for stimulants, while individual or family therapy can be time-consuming and expensive, reaching $1,000 or more.
"I hope it didn't do irreparable damage," study coauthor Lily Hechtman, MD, of McGill University in Montreal, told the Times. "The people who pay the price in the end [are] the kids. That's the biggest tragedy in all of this."